Vaxart May Be a COVID Vaccine Game Changer -- but Is It Too Late?
Vaxart (NASDAQ: VXRT) soared to stardom when its shares advanced 1,500% last year. The biotech company is developing a coronavirus-vaccine candidate in pill form. With 56% of Americans fully vaccinated, though, your question now may: Will Vaxart be too late to carve out market share?